

DMJ VOLUME 23 ARTICLE REFERENCES

OBESITY AND SURGERY

- 1) Dixon JB, O'Brien PE Outcomes after Lap Band placement: Changes in comorbidities and improvements in quality of life. *Am. J. Surg.* 2002; 184 (suppl):51-54
- 2) O'Brien PE, et.al. Treatment of mild to moderate obesity with laparoscopic adjustable gastric banding or/and intensive medical program. A randomized trial. *Ann Inter Med.*2006;144(9)0625-634

REDUCING FOOT PRESSURE

1. Palumbo P, Melton L. Peripheral vascular disease and diabetes. Bethesda, MD: National Institute of Health; 1985
2. Pecoraro RE, Reiber GE, EM B. Pathways to diabetic limb amputation: Basis for prevention. *Diabetes Care* 1990; 13:513-521
3. Thomson FJ, Veves A, Ashe H, Boulton AJM. A team approach to foot care: the Manchester experience. *The Foot* 1991; 1:75-82
4. International Working Group on the Diabetic Foot. International consensus on the Diabetic Foot and Practical Guidelines on the management and prevention of the diabetic foot. International Working Group on the Diabetic Foot/Consultative Selection of the International Diabetes Federation 2007
5. Macfarlane RM, Jeffcoate WL. Factors contributing to the presentation of diabetic foot ulcers. *Diabetic Medicine* 1997; 14(10):867-870
6. Steed DL, Donohoe D, Webster MW, Lindsley L. Effect of extensive debridement and treatment on the healing of diabetic foot ulcers. *Journal of the American College of Surgery* 1996; 183(1):61-64
7. Payne C. The theoretical mechanisms for the effectiveness of total contact casting in the management of diabetic foot ulcers. *Australasian Journal of Podiatric Medicine* 2001; 35(1):15
8. Shaw JE, Hsi WL, Ulbrecht JS, Norkitis A, Becker MB, Cavanagh PR. The mechanism of plantar unloading in total contact casts: implications for design and clinical use. *Foot & Ankle International* 1997;18:809-817
9. Conti SF, Martin RL, Chaytor ER, Hughes C, Luttrell L. Plantar pressure measurements during ambulation in weightbearing conventional short leg casts and total contact casts. *Foot and Ankle International* 1996; 17(8):464-469
10. Fleischli JG, Lavery LA, Vela SA, Ashry H, Lavery DC. Comparison of strategies for reducing pressure at the site of neuropathic ulcers. *Journal of the American Podiatric Medical Association* 1997; 87(10):466-472
11. Walker SC, Helm PA, Pullium G. Total contact casting and chronic diabetic neuropathic foot ulcerations: healing rates by wound location. *Archives of Physical Medicine and Rehabilitation* 1987; 68(4):217-221
12. Hartsell HD, Fellner C, Saltzman CL. Pneumatic bracing and total contact casting have equivocal effects on plantar pressure relief. *Foot and Ankle International* 2001; 22(6):502-506
13. Birke JA, Sims DS, Buford WL. Walking casts: effect on plantar foot pressures. *Journal of Rehabilitation Research and Development* 1985; 22(3):18-22
14. Baumhauer JF, Wurvey R, McWilliams J, Harris GF, Shereff MJ. A comparison of plantar foot pressure in a standardized shoe, total contact cast, and prefabricated pneumatic walking brace. *Foot and Ankle International* 1997; 18(1): 26-33
15. Armstrong DG, Nguyen HC, Lavery LA, Van Schie CHM, Boulton AJM, Harkless LB. Off-loading the diabetic foot wound: a randomised control trial. *Diabetes Care* 2001; 24(6):1019-1022
16. Birke JA, Pavich MA, Patout Jr CA, Horswell R. Comparison of forefoot ulcer healing using alternative offloading methods in patients with diabetes mellitus. *Advances in Skin and Woundcare* 2002; 15(5):210-215
17. Boulton AJM, Kirsner RS, Vileikyte L. Neuropathic diabetic foot ulcers. *New England Journal of Medicine* 2004; 351(1):48-55

DIABETIC EYE DISEASE, NON RETINOPATHY

1. Management of diabetic retinopathy: Clinical practice guidelines. NHMRC 1997.
<http://www.nhmrc.gov.au/publications/synopses/cp53covr.htm>
2. Ederer F, Hiller R, Taylor HR. Senile lens changes and diabetes in two population studies. *Am.J.Ophthalmol.* 1981;91:381-395.

3. Mitra RA, Borrillo JL, Dev S et al. Retinopathy progression and visual outcomes after phacoemulsification in patients with diabetes mellitus. *Arch Ophthalmol* 2000;**118**:912-917.
4. Dowler JG, Hykin PG, Lightman SL, Hamilton AM. Visual acuity following extracapsular cataract extraction in diabetes: a meta-analysis. *Eye* 1995;**9**:313-317.
5. Chew EY, Benson WE, Remaley NA et al. Results after lens extraction in patients with diabetic retinopathy: early treatment diabetic retinopathy study report number 25. *Arch Ophthalmol* 1999;**117**:1600-1606.

METABOLIC SYNDROME

1. Global prevalence of diabetes. Estimates for the year 2000 and projections for 2030. Wild S, Roglic G, Green A, Sicree R, King H. *Diabetes Care* 2004; **27**(5): 1047–53.
2. Joslin EP. The prevention of diabetes mellitus. *JAMA* 1921;**76**:79–84.
3. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. *Diabetes* 1988;**37**:1595-607. [PMID 3056758](#).
4. Jean-Philippe Empana , Pierre Ducimetiere , Beverley Balkau , and Xavier Jouven. Contribution of the metabolic syndrome to sudden death risk in asymptomatic men: the Paris Prospective Study I European Heart Journal Advance Access published on May 1, 2007, DOI 10.1093/eurheartj/ehm063. *Eur Heart J* 28: 1149-1154.
5. The IDF consensus worldwide definition of the metabolic syndrome. http://www.idf.org/webdata/docs/IDF_syndrome. http://www.idf.org/webdata/docs/MetS_def_update2006.pdf
6. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications. classification of diabetes mellitus and its complications. Report of a WHO consultation 1999.
7. Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance(EGIR). *Diabet Med* 1999;**16**:442–443.
8. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program(NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults(Adult Treatment Panel III). *JAMA* 2001;**285**:2486-97.
9. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F. Diagnosis and Management of the Metabolic Syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. *Circulation* 2006;**113**(19):2363-72.
10. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. *J Am Coll Cardiol*. 2007 Jan 30;**49**(4):403-14. Epub 2007 Jan 12. [Gami AS](#), [Witt BJ](#), [Howard DE](#), [Erwin PJ](#), [Gami LA](#), [Somers VK](#), [Montori VM](#).
11. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. *JAMA*. 2002 Dec 4;**288**(21):2709-16. [Lakka HM](#), [Laaksonen DE](#), [Lakka TA](#), [Niskanen LK](#), [Kumpusalo E](#), [Tuomilehto J](#), [Salonen JT](#).
12. Metabolic syndrome and the risk of cardiovascular disease in older adults. [Butler J](#), [Rodondi N](#), [Zhu Y](#), [Figaro K](#), [Fazio S](#), [Vaughan DE](#), [Satterfield S](#), [Newman AB](#), [Goodpaster B](#), [Bauer DC](#), [Holvoet P](#), [Harris TB](#), [de Rekeneire N](#), [Rubin S](#), [Ding J](#), [Kritchevsky SB](#); [Health ABC Study](#). *J Am Coll Cardiol*. 2006 Apr 18;**47**(8):1595-602. Epub 2006 Mar 27.
13. Franco OH, Steyerberg EW, Hu FB, et al. Associations of diabetes mellitus with total life expectancy and life expectancy with and without cardiovascular disease. *Arch Intern Med* 2007; **167**:1145-1151.
14. Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. *Endocr Rev* 2000;**21**(6):697-738
15. Analysis of obesity and hyperinsulinemia in the development of metabolic syndrome: San Antonio Heart Study. [Han TS](#), [Williams K](#), [Sattar N](#), [Hunt KJ](#), [Lean ME](#), [Haffner SM](#). : *Obes Res*. 2002 Sep;**10**(9):923-31
16. Waist Circumference Predicts Cardio metabolic and Global Framingham Risk among Women Screened during National Woman's Heart Day. Lori Mosca, Dana Edelman, Heidi Mochari, Allison H. Christian, Furcy Paultre, Irene Pollin, *Journal of Women's Health* vol 15: Nov 2006
17. Collins R, MacMahon S. Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. *British Medical Bulletin*. 1994;**50**(2):272-98.

18. Vasan, Ramachandran S., Larson, Martin G., Leip, Eric P., Evans, Jane C., O'Donnell, Christopher J., Kannel, William B., Levy, Danie. Impact of High-Normal Blood Pressure on the Risk of Cardiovascular Disease N Engl J Med 2001 345: 1291-1297
19. Subclinical organ damage in essential hypertensive patients with the metabolic syndrome
Leoncini G, Ratto E, Viazzi F, Vaccaro V, Parodi D, Parodi A, Falqui V, Tomolillo C, Deferrari G, Pontremoli R. J Intern Med 2005;257:454-60.
20. Grundy SM, Brewer HB, Cleeman JI, et al, for the Conference Participants. Definition of metabolic syndrome. Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition. Circulation. 2004;109:433-438.
21. Austin MA, Edwards KL. Small, dense low density lipoproteins, the insulin resistance syndrome and noninsulin-dependent diabetes. Curr Opin Lipidol 1996;7:167-171.
22. M. A. Austin; J. L. Breslow; C. H. Hennekens; J. E. Buring; W. C. Willett; R. M. Krauss Low-density lipoprotein subclass patterns and risk of myocardial infarction JAMA 1988 260: 1917-1921
23. Physical Activity, Obesity Status, and Glycemic Control: The ATTICA Study Stavros A. Kavouras; Demosthenes B. Panagiotakos; Christos Pitsavos; Christina Chrysohoou; Costas A. Anastasiou; Yannis Lentzas; Christodoulos Stefanadis Med Sci Sports Exerc. 2007;39(4):606-611.
24. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.
Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. : N Engl J Med. 2003 Jan 30;348(5):383-93
25. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE sub-study. Lancet. 2000;355:253-259.
26. Fox KM, Henderson JR, Bertrand ME, Ferrari R, Remme WJ, Simoons ML. The European trial on reduction of cardiac events with perindopril in stable coronary artery disease (EUROPA). Eur Heart J. 1998 Sep;19 Suppl J:J52-5.
27. Elliott WJ, Meyer PM Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 369; 201-207
- 27a. Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system. Journal of Hypertension. 22(12):2253-2261, December 2004. Kurtz, Theodore W a; Pravenec, Michal b
28. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study Deedwania P, Barter P, Carmena R, Fruchart JC, Grundy SM, Haffner S, Kastelein JJ, LaRosa JC, Schachner H, Shepherd J, Waters DD, for the Treating to New Targets Investigators The Lancet - Vol. 368, Issue 9539, 09 September 2006, Pages 919-928
29. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesäniemi YA, Sullivan D, Hunt D, Colman P, d'Emden M, Whiting M, Ehnholm C, Laakso M; FIELD study investigators. Lancet. 2005 Nov 26;366(9500):1849-61.
30. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-865.
31. The Effect of Metformin and Intensive Lifestyle Intervention on the Metabolic Syndrome: The Diabetes Prevention Program Randomized Trial." It is in the 19 April 2005 issue of Annals of Internal Medicine (volume 142, pages 611-619). The authors are T.J. Orchard, M. Temprosa, R. Goldberg, S. Haffner, R. Ratner, S. Marcovina, and S. Fowler, for the Diabetes Prevention Program Research Group.
32. American Diabetes Association. Complications of diabetes in the United States.
[Http://www.diabetes.org/diabetes-statistics/complications.jsp](http://www.diabetes.org/diabetes-statistics/complications.jsp)
33. Erdmann E, Dormandy JA, Charbonnel B. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction. Results from the PROactive study. J Am Coll Cardiol 2007; 49:1772-1780.
- Westerbacka J. PROactive in patients with type 2 diabetes and previous myocardial infarction. Swinging the sword of Damocles? J Am Coll Cardiol 2007; 49:1781-1782.
34. Strom BL. Statement for the hearing of the United States House of Representatives Committee on Oversight and Government Reform, June 7, 2007.
- Nissen SE and Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356:2457-71

35. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes—an interim analysis. *N Engl J Med* 2007; DOI: 0.1056/NEJMoa073394.
36. Norris SL, Zhang X, Avenell A, et al. Efficacy of pharmacotherapy for weight loss in adults with type 2 diabetes mellitus: A meta-analysis. *Arch Intern Med* 2004;164:1395-1404.
37. Jonsson KO, Holt S, Fowler CJ. The endocannabinoid system: current pharmacological research and therapeutic possibilities. *Basic Clin Pharmacol Toxicol* 2006; 98: 124-34.
38. <http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4306b1-fda-background.pdf>
39. Results of Bariatric Surgery. Erik N. Hansen, Alfonso Torquati, Naji N. Abumrad *Annual Review of Nutrition* 2006 26, 481-511
40. Diamond GA, Kaul S, Shah PK, et al. Screen testing: Cardiovascular prevention in asymptomatic diabetic patients. *J Am Coll Cardiol* 2007; 49:1915-1917.
41. Beller GA. Noninvasive screening for coronary atherosclerosis and silent ischemia in asymptomatic type 2 diabetic patients: Is it appropriate and cost-effective? *J Am Coll Cardiol* 2007; 49:1918-1923.

DDP-4 INHIBITORS

1. Nauck, M., Stockmann, F., Ebert, R., and Creutzfeldt, W. 1986. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. *Diabetologia* 29:46-52.
2. Toft-Nielsen, M.B., Damholt, M.B., Madsbad, S., Hilsted, L.M., Hughes, T.E., Michelsen, B.K., and Holst, J.J. 2001. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. *J Clin Endocrinol Metab* 86:3717-3723.
3. Rachman, J., Barrow, B.A., Levy, J.C., and Turner, R.C. 1997. Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM. *Diabetologia* 40:205-211.
4. Amori, R.E., Lau, J., and Pittas, A.G. 2007. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. *Jama* 298:194-206.
5. Nikolaidis, L.A., Mankad, S., Sokos, G.G., Miske, G., Shah, A., Elahi, D., and Shannon, R.P. 2004. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. *Circulation* 109:962-965.

COELIAC D AND DIABETES

1. Green PH, Jabri B. Celiac disease. *Annu Rev Med* 2006; 57:207-21.
2. Anderson RP. Coeliac disease: current approach and future prospects. *Int Med J* 2008 in press.
3. Walter M, McDonald CG, Paty BW, Shapiro AM, Ryan EA, Senior PA. Prevalence of autoimmune diseases in islet transplant candidates with severe hypoglycaemia and glycaemic lability: previously undiagnosed coeliac and autoimmune thyroid disease is identified by screening. *Diabet Med.* 2007; 24:161-5.

OSTEOPOROSIS AND DIABETES

1. Meier C, Kraenzlin ME, Bodmer M, Jick SS, Jick H, Meier CR. Use of Thiazolidinediones and Fracture Risk. *Arch Intern Med.* 2008; 168(8):820-825.
2. Yamamoto M, Yamaguchi T, Yamauchi M, Yano S, Sugimoto T. Serum pentosidine levels are positively associated with the presence of vertebral fractures in postmenopausal women with type 2 diabetes. *J Clin Endocrinol Metab.* 2008; doi:10.1210/jc.2007-1270.
3. Epstein S, LeRoith D. Diabetes and fragility fractures—A burgeoning epidemic? *Bone* 2008; doi: 10.1016/j.bone.2008.03.017.
4. Hofbauer LC, Brueck CC, Singh SK, Dobnig H. Osteoporosis in patients with diabetes mellitus. *J Bone Miner Res* 2007; 22:1317–1328.

5. Grey A, Bolland M, Gamble G, et al. The peroxisome proliferator-activated receptor- α agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. *J Clin Endocrinol Metab.* 2007;92(4):1305-1310.
6. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. *N Engl J Med.* 2006; 355(23):2427-2443.
7. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. *N Engl J Med.* 2006; 355(23):2427-2443.
8. Meier C, Kraenzlin ME, Bodmer M, Jick SS, Jick H, Meier CR. Use of Thiazolidinediones and Fracture Risk. *Arch Intern Med.* 2008; 168(8):820-825.

DIABETES AND STROKE REFERENCES

1. Kissela BM, Khoury J, Kleindorfer D, Woo D, Schneider A, Alwell K, Miller R, Ewing I, Moomaw CJ, Szaflarski JP, Gebel J, Shukla R, Broderick JP. Epidemiology of ischemic stroke in patients with diabetes: The greater cincinnati/northern kentucky stroke study. *Diabetes Care.* 2005;28:355-359
2. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. *N Engl J Med.* 2005;353:2643-2653
3. Allport L, Baird T, Butcher K, Macgregor L, Prosser J, Colman P, Davis S. Frequency and temporal profile of poststroke hyperglycemia using continuous glucose monitoring. *Diabetes Care.* 2006;29:1839-1844
4. Parsons MW, Barber PA, Desmond PM, Baird TA, Darby DG, Byrnes G, Tress BM, Davis SM. Acute hyperglycemia adversely affects stroke outcome: A magnetic resonance imaging and spectroscopy study. *Ann Neurol.* 2002;52:20-28
5. Allport LE, Butcher KS, Baird TA, MacGregor L, Desmond PM, Tress BM, Colman P, Davis SM. Insular cortical ischemia is independently associated with acute stress hyperglycemia. *Stroke.* 2004;35:1886-1891
6. Berthet K, Neal BC, Chalmers JP, MacMahon SW, Bousser MG, Colman SA, Woodward M. Reductions in the risks of recurrent stroke in patients with and without diabetes: The progress trial. *Blood Press.* 2004;13:7-13
7. Gray CS, Hildreth AJ, Sandercock PA, O'Connell JE, Johnston DE, Cartlidge NE, Bamford JM, James OF, Alberti KG. Glucose-potassium-insulin infusions in the management of post-stroke hyperglycaemia: The UK glucose insulin in stroke trial (GIST-UK). *Lancet Neurol.* 2007;6:397-406

VEGETARIAN DIET & DIABETES

1. Sabat, J., The contribution of vegetarian diets to human health. *Forum Nutr*, 2003. **56**: p. 218-20.
2. Sabat, J., The contribution of vegetarian diets to health and disease: a paradigm shift? *Am J Clin Nutr*, 2003. **78**(3 Suppl): p. 502S-507S.
3. Snowdon, D.A. and R.L. Phillips, Does a vegetarian diet reduce the occurrence of diabetes? *Am J Public Health*, 1985. **75**(5): p. 507-12.
4. Jiang, R., et al., Dietary iron intake and blood donations in relation to risk of type 2 diabetes in men: a prospective cohort study. *Am J Clin Nutr*, 2004. **79**(1): p. 70-5.
5. Lee, D.H., A.R. Folsom, and D.R. Jacobs, Dietary iron intake and Type 2 diabetes incidence in postmenopausal women: the Iowa Women s Health Study. *Diabetologia*, 2004. **47**(2): p. 185-94.
6. Luan, D.C., et al., Body Iron Stores and Dietary Iron Intake in Relation to Diabetes in Adults in North China. *Diabetes Care*, 2007.
7. Song, Y., et al., A prospective study of red meat consumption and type 2 diabetes in middle-aged and elderly women: the women s health study. *Diabetes Care*, 2004. **27**(9): p. 2108-15.
8. Fung, T.T., et al., Dietary patterns, meat intake, and the risk of type 2 diabetes in women. *Arch Intern Med*, 2004. **164**(20): p. 2235-40.

9. Schulze, M.B., et al., Processed meat intake and incidence of Type 2 diabetes in younger and middle-aged women. *Diabetologia*, 2003. **46**(11): p. 1465-73.
10. Vang, A., et al., Meats, Processed Meats, Obesity, Weight Gain and Occurrence of Diabetes among Adults: Findings from Adventist Health Studies. *Ann Nutr Metab*, 2008. **52**(2): p. 96-104.
11. Zhang, C., et al., A prospective study of dietary patterns, meat intake and the risk of gestational diabetes mellitus. *Diabetologia*, 2006. **49**(11): p. 2604-13.
12. Panagiotakos, D.B., et al., The relationship between dietary habits, blood glucose and insulin levels among people without cardiovascular disease and type 2 diabetes; the ATTICA study. *Rev Diabet Stud*, 2005. **2**(4): p. 208-15.
13. Lindström, J., et al., High-fibre, low-fat diet predicts long-term weight loss and decreased type 2 diabetes risk: the Finnish Diabetes Prevention Study. *Diabetologia*, 2006. **49**(5): p. 912-20.
14. Boeing, H., et al., Association between glycosylated hemoglobin and diet and other lifestyle factors in a nondiabetic population: cross-sectional evaluation of data from the Potsdam cohort of the European Prospective Investigation into Cancer and Nutrition Study. *Am J Clin Nutr*, 2000. **71**(5): p. 1115-22.
15. Krishnan, S., et al., Glycemic index, glycemic load, and cereal fiber intake and risk of type 2 diabetes in US black women. *Arch Intern Med*, 2007. **167**(21): p. 2304-9.
16. Liu, S., et al., A prospective study of whole-grain intake and risk of type 2 diabetes mellitus in US women. *Am J Public Health*, 2000. **90**(9): p. 1409-15.
17. Marshall, J.A., D.H. Bessesen, and R.F. Hamman, High saturated fat and low starch and fibre are associated with hyperinsulinaemia in a non-diabetic population: the San Luis Valley Diabetes Study. *Diabetologia*, 1997. **40**(4): p. 430-8.
18. Salmeron, J., et al., Dietary fiber, glycemic load, and risk of NIDDM in men. *Diabetes Care*, 1997. **20**(4): p. 545-50.
19. Salmeron, J., et al., Dietary fiber, glycemic load, and risk of non-insulin-dependent diabetes mellitus in women. *Jama*, 1997. **277**(6): p. 472-7.
20. Liese, A.D., et al., Whole-grain intake and insulin sensitivity: the Insulin Resistance Atherosclerosis Study. *Am J Clin Nutr*, 2003. **78**(5): p. 965-71.
21. Pereira, M.A., et al., Effect of whole grains on insulin sensitivity in overweight hyperinsulinemic adults. *Am J Clin Nutr*, 2002. **75**(5): p. 848-55.
22. Jiang, R., et al., Nut and peanut butter consumption and risk of type 2 diabetes in women. *JAMA*, 2002. **288**(20): p. 2554-60.
23. Villegas, R., et al., Legume and soy food intake and the incidence of type 2 diabetes in the Shanghai Women's Health Study. *Am J Clin Nutr*, 2008. **87**(1): p. 162-7.
24. de Mello, V.D., et al., Withdrawal of red meat from the usual diet reduces albuminuria and improves serum fatty acid profile in type 2 diabetes patients with macroalbuminuria. *Am J Clin Nutr*, 2006. **83**(5): p. 1032-8.
25. Jibani, M.M., et al., Predominantly vegetarian diet in patients with incipient and early clinical diabetic nephropathy: effects on albumin excretion rate and nutritional status. *Diabet Med*, 1991. **8**(10): p. 949-53.
26. Stephenson, T.J., et al., Effect of soy protein-rich diet on renal function in young adults with insulin-dependent diabetes mellitus. *Clin Nephrol*, 2005. **64**(1): p. 1-11.
27. Azadbakht, L., S. Atabak, and A. Esmailzadeh, Soy Protein Intake, Cardiorenal Indices, and C-Reactive Protein in Type 2 Diabetes With Nephropathy: A longitudinal randomized clinical trial. *Diabetes Care*, 2008. **31**(4): p. 648-654.
28. Appleby, P.N., et al., The Oxford Vegetarian Study: an overview. *Am J Clin Nutr*, 1999. **70**(3 Suppl): p. 525S-531S.
29. Hu, F.B., Plant-based foods and prevention of cardiovascular disease: an overview. *Am J Clin Nutr*, 2003. **78**(3 Suppl): p. 544S-551S.
30. Jenkins, D.J., et al., Type 2 diabetes and the vegetarian diet. *Am J Clin Nutr*, 2003. **78**(3 Suppl): p. 610S-616S.
31. Barnard, N.D., et al., A low-fat vegan diet improves glycemic control and cardiovascular risk factors in a randomized clinical trial in individuals with type 2 diabetes. *Diabetes Care*, 2006. **29**(8): p. 1777-83.
32. Barnard, R.J., T. Jung, and S.B. Inkeles, Diet and exercise in the treatment of NIDDM. The need for early emphasis. *Diabetes Care*, 1994. **17**(12): p. 1469-72.
33. Nicholson, A.S., et al., Toward improved management of NIDDM: A randomized, controlled, pilot intervention using a lowfat, vegetarian diet. *Prev Med*, 1999. **29**(2): p. 87-91.

NAFLD

1. AGA, *American Gastroenterological Association medical position statement: Nonalcoholic fatty liver disease. Gastroenterology*, 2002; 123(5):1702-1704.
2. Sanyal AJ, AGA *technical review on nonalcoholic fatty liver disease. Gastroenterology*, 2002; 123(5):1705-1725.
3. Cameron AJ, Welborn TA, Zimmet PZ, et al., *Overweight and obesity in Australia: the 1999-2000 Australian Diabetes, Obesity and Lifestyle Study (AusDiab). Med J Aust*, 2003; 178(9):427-32.
4. Ludwig J, Viggiano TR, McGill DB, Oh BJ, *Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc*, 1980; 55(7):434-8.
5. Adams LA, Lymp JF, St. Sauver J, et al., *The Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study. Gastroenterology*, 2005; 129(1):113-121.
6. Ekstedt M, Franzén L, Mathiesen U, et al., *Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology*, 2006; 44(4):865-873.
7. Charlton, *Nonalcoholic fatty liver disease: A review of current understanding and future impact. Clinical Gastroenterology and Hepatology*, 2004; 2(12):1048-1058.
8. Hickman IJ, Clouston AD, Macdonald GA, et al., *Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. Gut*, 2002; 51(1):89-94.
9. Alberti KGM, Zimmet P, Shaw J, *The metabolic syndrome--a new worldwide definition. The Lancet*, 2005; 366(9491):1059-1062.
10. Ratziu V, Giral P, Charlotte F, et al., *Liver fibrosis in overweight patients. Gastroenterology*, 2000; 118(6):1117-23.
11. Dixon J, Bhathal P, Hughes N, O'Brien P, *Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss. Hepatology*, 2004; 39(6):1647-1654.